Combination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients.

Abstract

HomeHypertensionVol. 80, No. 3Combination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients No AccessLetterRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessLetterRequest AccessFull TextCombination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients Isik Turker, Ananya Sharma, Shi Huang, Douglas B. Johnson and Matthew R. Alexander Isik TurkerIsik Turker https://orcid.org/0000-0003-3216-3499 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN (I.T., M.R.A.). Department of Medicine, Division of Cardiology, Washington University School of Medicine, St Louis, MO (I.T.). Search for more papers by this author , Ananya SharmaAnanya Sharma https://orcid.org/0000-0001-6592-5811 Vanderbilt University School of Medicine, Nashville, TN (A.S.). Search for more papers by this author , Shi HuangShi Huang Department of Biostatistics, Vanderbilt University, Nashville, TN (S.H.). Search for more papers by this author , Douglas B. JohnsonDouglas B. Johnson Department of Medicine, Division of Hematology and Oncology, VUMC, Nashville, TN (D.B.J.). Search for more papers by this author and Matthew R. AlexanderMatthew R. Alexander Correspondence to: Matthew R. Alexander, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2215 Garland Ave, 560B RRB Nashville, TN 37232, Email E-mail Address: [email protected] https://orcid.org/0000-0003-4739-7204 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN (I.T., M.R.A.). Department of Medicine, Division of Clinical Pharmacology, VUMC, Nashville, TN (M.R.A.). Vanderbilt Institute for Infection, Immunology, and Inflammation, VUMC, Nashville, TN (M.R.A.). Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN (M.R.A.). Search for more papers by this author Originally published18 Nov 2022https://doi.org/10.1161/HYPERTENSIONAHA.122.20407Hypertension. 2023;80:e43–e45FootnotesFor Sources of Funding and Disclosures, see page e45.Correspondence to: Matthew R. Alexander, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2215 Garland Ave, 560B RRB Nashville, TN 37232, Email matt.[email protected]org